Endocrine Abstracts

Introduction: Agonist receptor-GLP1 (AR-GLP1) had demonstrated its utility in obese patients with diabetes type 2. Since August 2013 we have available in Spain a new AR-GLP1 with prandial action in a single daily dose, lixisenatide. There are different clinical trials that support its efficacy and security but the dates from real clinical practice are scarce.Aim: To analyse the efficacy and security in real clinical practice for the treatment of diabetic...